Industry

DUBLIN–(BUSINESS WIRE)–The “DNA Specimen Collector” training has been added to ResearchAndMarkets.com’s offering. This course prepares students to conduct buccal swab collections and the accompanying paperwork to be sent to any DNA testing laboratory for testing. Become a Certified Professional DNA/Paternity Collector and help donors learn the truth about their child’s paternity. This is a great … [Read more…]

Leading Telehealth Provider of Substance Use Disorder (SUD) Treatment Shares Expert Advice on How to #StopTheStigma at Work for This Year’s Campaign REDWOOD CITY, Calif.–(BUSINESS WIRE)–#NORD–Lionrock, the inventor of online substance use disorders (SUDs) treatment and recovery services in the United States, today announced the theme for the third annual National Online Recovery Day campaign: … [Read more…]

LifeWorks Financial Wellbeing Index™ finds half of Canadians feel the biggest impact of inflation in the cost of groceries TORONTO–(BUSINESS WIRE)–LifeWorks, a leading provider of digital and in-person total wellbeing solutions, today released its quarterly Financial Wellbeing Index™. The report showed that 29 per cent of Canadians are concerned about their ability to cover basic … [Read more…]

DentalMonitoring is Making Industry History with the Launch of DM Insights, the First and Only Clinical Data Analysis Platform to Drive Enhanced Workflows in Dental and Orthodontic Practices PARIS–(BUSINESS WIRE)–DM Insights joins the DM Intelligent Platform, DentalMonitoring’s full suite of solutions designed to improve the quality of care and the patient experience while growing practices … [Read more…]

 A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic and operational roadmap for future commercialization. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation … [Read more…]

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on Sanofi’s proprietary multifunctional CROSSDILES® platform and Innate’s proprietary multi-specific NK cell engager platform, ANKETTM targeting BCMA, selected by Sanofi for IND-enabling studies, with €3M milestone payment … [Read more…]

Leadership team reinforced for next phase in Protembis’ clinical and regulatory growth trajectory AACHEN, Germany–(BUSINESS WIRE)–#CerebralProtection—Protembis GmbH, a privately-held emerging cardiovascular medical device company, announced today the appointment of highly experienced and successful serial entrepreneur and medical device executive Azin Parhizgar (Ph.D.) as an Independent Member and Chairwoman of the Board of Directors. Azin remains … [Read more…]

CHICAGO–(BUSINESS WIRE)–The Chicago Chapter of the Dragonfly Foundation received a $5,000 grant from the SBB Research Group Foundation, which awards monthly grants to support impactful organizations during the pandemic. The Dragonfly Foundation partners with local hospitals to fulfill the everyday needs of children with cancer and their families. Since 2010, the Cincinnati-headquartered nonprofit has assisted … [Read more…]

BEIJING & GUANGZHOU, China–(BUSINESS WIRE)–#Biocytogen–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell … [Read more…]

Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103) The phase 1/2 study of Q901 and KEYTRUDA is designed to enroll patients with advanced solid tumors SEONGNAM-SI, South Korea–(BUSINESS WIRE)–#Qurient—Qurient Co. Ltd. (KRX: 115180), a clinical-stage … [Read more…]